Krystal 7 Study: Adagrasib +/- Pembrolizumab for KRAS G12C+ NSCLC -Targeted Therapies in Lung Cancer

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins.

In this video, Dr. Joshua Sabari discusses the Krystal 7 study, and gives a conclusion to his discussion on overall treatment options for KRAS+ NSCLC.

BenSound License #: DSSHUIYGV4VQCETM

Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.